In preclinical studies, the use of HDAC inhibitors has shown the ability to resensitize some cancer cells particularly to nucleoside analogs by disengaging the silencing of apoptotic genes and modulating the expression of DNA repair proteins [102,103]. Here, HDAC9 is linked to cancer.